FY2024 Earnings Forecast for Pfizer Issued By Zacks Research

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Zacks Research raised their FY2024 earnings per share (EPS) estimates for Pfizer in a research note issued to investors on Monday, November 18th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of $2.87 per share for the year, up from their prior forecast of $2.57. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share. Zacks Research also issued estimates for Pfizer’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.78 EPS and FY2026 earnings at $2.94 EPS.

A number of other equities analysts have also recently issued reports on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Pfizer Trading Up 1.0 %

Pfizer stock opened at $25.10 on Wednesday. Pfizer has a 1 year low of $24.48 and a 1 year high of $31.54. The firm’s 50 day moving average price is $28.45 and its two-hundred day moving average price is $28.63. The firm has a market cap of $142.24 billion, a price-to-earnings ratio of 33.92, a price-to-earnings-growth ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the firm earned ($0.17) EPS. The business’s revenue for the quarter was up 31.2% on a year-over-year basis.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.69%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently made changes to their positions in the stock. TD Private Client Wealth LLC lifted its holdings in Pfizer by 2.7% in the 3rd quarter. TD Private Client Wealth LLC now owns 124,712 shares of the biopharmaceutical company’s stock worth $3,609,000 after purchasing an additional 3,307 shares during the last quarter. Arete Wealth Advisors LLC bought a new position in shares of Pfizer in the third quarter valued at approximately $1,871,000. Empire Financial Management Company LLC lifted its stake in shares of Pfizer by 1.1% in the third quarter. Empire Financial Management Company LLC now owns 95,304 shares of the biopharmaceutical company’s stock worth $2,758,000 after buying an additional 1,000 shares during the last quarter. Neo Ivy Capital Management boosted its holdings in shares of Pfizer by 1,261.5% during the 3rd quarter. Neo Ivy Capital Management now owns 77,168 shares of the biopharmaceutical company’s stock worth $2,234,000 after buying an additional 71,500 shares during the period. Finally, Financial Avengers Inc. grew its stake in Pfizer by 52.1% in the 3rd quarter. Financial Avengers Inc. now owns 27,942 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 9,568 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.